# Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer

> **NCT00967655** · PHASE2 · UNKNOWN · sponsor: **Loma Linda Oncology Medical Group, Inc.** · enrollment: 54 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** panitumumab
- **DRUG:** capecitabine
- **DRUG:** irinotecan hydrochloride
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00967655
- **Lead sponsor:** Loma Linda Oncology Medical Group, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-07
- **Primary completion:** 2012-07
- **Final completion:** —
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2014-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967655, "Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00967655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*